Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy’s Laboratories Ltd, on Thursday ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Shares of Dr. Reddy’s Laboratories Ltd ADR (NYSE:RDY) climbed 3.1% in premarket trading today following the announcement of a collaboration and license agreement with Alvotech to co-develop, ...

Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

On Thursday, 2257 stocks advanced, 1725 declined and 147 remained unchanged on Bombay Stock Exchange with advance decline ...